SCHEMBL3928328

SCHEMBL3928328

CCC(CC)c1cc(C)nn2c(-c3sc(-c4ccc(F)cc4)nc3C)c(C)nc12

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRHR1 P34998 3/20 0.66
CRHR2 Q13324 1/20 0.50
MEN1 O00255 4/20 0.38
KMT2A Q03164 4/20 0.38
RAB9A P51151 3/20 0.38
MAPT P10636 3/20 0.38
NPC1 O15118 2/20 0.38
KDM4E B2RXH2 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TRPM8 Q7Z2W7 1/20 0.37
SMPD3 Q9NY59 2/20 0.36
POLB P06746 2/20 0.34
TSHR P16473 1/20 0.34
HSD17B10 Q99714 1/20 0.34
STAT1 P42224 1/20 0.34
TSPO P30536 1/20 0.33
APP P05067 1/20 0.33
ALDH1A1 P00352 1/20 0.33
CASP3 P42574 1/20 0.33
BLM P54132 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3931718 0.90 CRHR1 (0.59) CRHR1CRHR2MEN1KMT2ARAB9A
SCHEMBL3932174 0.90 CRHR1 (0.57) CRHR1CRHR2MEN1KMT2ARAB9A
SCHEMBL3924154 0.89 CRHR1 (0.63) CRHR1CRHR2MAPTTRPM8LMNA
SCHEMBL3923295 0.89 CRHR1 (0.56) CRHR1CRHR2KMT2ARAB9ANPC1
SCHEMBL3933558 0.87 CRHR1 (0.66) CRHR1CRHR2MEN1KMT2ARAB9A
SCHEMBL3922878 0.87 CRHR1 (0.66) CRHR1CRHR2MEN1KMT2ARAB9A
SCHEMBL3926292 0.87 CRHR1 (0.53) CRHR1CRHR2SMPD3
SCHEMBL3926194 0.85 CRHR1 (0.60) CRHR1CRHR2SMPD3HSD17B10ALDH1A1
SCHEMBL3926806 0.85 CRHR1 (0.65) CRHR1CRHR2MEN1KMT2ARAB9A
SCHEMBL3923339 0.84 CRHR1 (0.54) CRHR1CRHR2MEN1KMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612067-B2 Imidazopyridazine compounds ELI LILLY AND COMPANY (US) 2009-11-03 US disclosed
US-7612067-B2 Imidazopyridazine compounds ELI LILLY AND COMPANY (US) 2009-11-03 US disclosed
US-7612067-B2 Imidazopyridazine compounds ELI LILLY AND COMPANY (US) 2009-11-03 US disclosed
EP-1869049-B1 IMIDAZOPYRIDAZINE COMPOUNDS LILLY CO ELI (US) 2009-03-04 EP disclosed
US-20080113978-A1 Imidazopyridazine Compounds ELI LILLY AND COMPANY 2008-05-15 US disclosed
US-20080113978-A1 Imidazopyridazine Compounds ELI LILLY AND COMPANY 2008-05-15 US disclosed
US-20080113978-A1 Imidazopyridazine Compounds ELI LILLY AND COMPANY 2008-05-15 US disclosed
EP-1869049-A1 IMIDAZOPYRIDAZINE COMPOUNDS ELI LILLY AND COMPANY (US) 2007-12-26 EP disclosed
WO-2006102194-A1 IMIDAZOPYRIDAZINE COMPOUNDS ELI LILLY AND COMPANY (US) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080113978-A1 Imidazopyridazine Compounds CRHR1, CRH, CRHR2 CRHR1 1/4885CRHR2 3/4885MEN1 1192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.